Skip to main content

Rahul D. Ballal, Ph.D.

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Rahul D. Ballal, Ph.D.

Rahul D. Ballal, Ph.D. is recorded as Board Member at Enliven Therapeutics, Inc. (ELVN). Enliven Therapeutics, Inc. reported in an 8-K filed March 1, 2023 that Rahul D. Ballal, Ph.D. was appointed Board, effective February 23, 2023. Enliven Therapeutics, Inc. reported in an 8-K filed March 1, 2023 that Rahul D. Ballal, Ph.D. resigned as President and Chief Executive Officer, effective February 23, 2023.

“Pursuant to the Merger Agreement, as of the effective time of the Merger, the size of the Board was fixed at nine members consisting of one member designated by the Company, Dr. Ballal, and all eight members of the board of directors of Former Enliven, namely Sam Kintz, M.B.A., Joseph Lyssikatos, Ph.D., Jake Bauer, Mika Derynck, M.D., Rishi Gupta, J.D., Richard Heyman, Ph.D., Andrew Phillips, Ph.D., and Andrew Schwab.”
Enliven Therapeutics, Inc. Form 8-K, filed March 1, 2023 · Read the filing
“On February 23, 2023, immediately prior to and effective upon the closing of the Merger, Rahul D. Ballal, Ph.D., resigned from his position as the Company’s President and Chief Executive Officer, and Michael P. Gray resigned from his position as the Company’s Chief Financial Officer and Chief Operating Officer.”
Enliven Therapeutics, Inc. Form 8-K, filed March 1, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Enliven Therapeutics, Inc.

Other people whose current roles at this company are on record from its filings.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.